Skip to content
Peptigraph home

KPV

Anti-inflammatory tripeptide. KPV is not FDA approved for any use.

Also called:Lys-Pro-Valalpha-MSH fragment
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Animal evidence, 2 of 4
StatusPCAC voted 8–6 for 503A (Jul 2026)Removed from FDA Category 2 on 15 Apr 2026. PCAC voted 8–6 for the 503A list (Jul 2026); not finalized.WADA status unclearFull legal history

Key facts

How we verify
Class
Anti-inflammatory tripeptide
Also called
Lys-Pro-Val, alpha-MSH fragment
Vial sizes sold
5 mg, 10 mg, 20 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026
PCAC vote
8–6 for 503A
Jul 2026, not final
WADA
Unclear
Not named on the 2026 list
Everything on KPV

KPV guides

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.Half-lifeWhat is measured, by route, and what is not.For inflammationWhat research says about KPV for inflammation.For gut healthWhat research says about KPV for gut health.For skinWhat research says about KPV for skin.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

KPV: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Inflammation10196Animal evidence, 2 of 4Inflammatory bowel diseases 2008, PMID 18092346
Gut health462Animal evidence, 2 of 4Inflammatory bowel diseases 2008, PMID 18092346
Skin113In vitro evidence, 1 of 4Tissue & cell 2025, PMID 40073467

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Compared with

KPVvsBPC-157Anti-inflammatory tripeptide next to gastric pentadecapeptide: evidence, dosing and legal status side by side.PCAC voted 8–6 for 503A (Jul 2026)Read the comparison →

Common stacks

KPV is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

KLOWGHK-Cu, BPC-157, TB-500 and KPV80 mg blendsBlend calculator
KPV + BPC-157KPV + GHK-Cu

Common questions

Is KPV FDA approved?

No. KPV is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee voted 8–6 in July 2026 to add it to the 503A compounding list. That vote is not final.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  3. 3US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "KPV" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  6. 6US compounding: KPV was removed from FDA's 503A category 2 after the nominator withdrew; FDA announced a PCAC consultation on 23 July 2026.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  7. 7Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
  8. 8Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.Tissue & cell · 2025PMID 40073467Accessed 2 Oct 2026
  9. 9PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  14. 14FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026

Found an error? Report a correction.